Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | F13A1 | P00488 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | FASN | P49327 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 6/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | TGM2 | P21980 | 3/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cerulenin SCHEMBL20528755 | 1.00 | ALDH1A1 (1.00) | ALDH1A1F13A1MAPTPTGS1THRB | |
| Cerulenin SCHEMBL3183350 | 1.00 | ALDH1A1 (1.00) | ALDH1A1F13A1MAPTPTGS1THRB | |
| Cerulenin SCHEMBL8678332 | 1.00 | ALDH1A1 (1.00) | ALDH1A1F13A1MAPTPTGS1THRB | |
| Cerulenin SCHEMBL41207 | 1.00 | ALDH1A1 (1.00) | ALDH1A1F13A1MAPTPTGS1THRB | |
| Cerulenin SCHEMBL28576416 | 1.00 | ALDH1A1 (1.00) | ALDH1A1F13A1MAPTPTGS1THRB | |
| Cerulenin SCHEMBL10387308 | 1.00 | ALDH1A1 (1.00) | ALDH1A1F13A1MAPTPTGS1THRB | |
| Cerulenin SCHEMBL8716153 | 1.00 | ALDH1A1 (1.00) | ALDH1A1F13A1MAPTPTGS1THRB | |
| SCHEMBL12902003 | 0.85 | ALDH1A1 (0.74) | ALDH1A1F13A1MAPTPTGS1THRB | |
| SCHEMBL17874340 | 0.85 | ALDH1A1 (0.74) | ALDH1A1F13A1MAPTPTGS1THRB | |
| SCHEMBL9453468 | 0.81 | ALDH1A1 (0.68) | ALDH1A1F13A1MAPTPTGS1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009151910-A2 | COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER | WYETH (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1565180-A4 | A METHOD FOR INHIBITING CANCER DEVELOPMENT BY FATTY ACID SYNTHASE INHIBITORS | FASGEN LLC (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070142456-A1 | Method for inhibiting cancer development by fatty acid synthase inhibitors | FASGEN, LLC (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1565180-A2 | A METHOD FOR INHIBITING CANCER DEVELOPMENT BY FATTY ACID SYNTHASE INHIBITORS | Fasgen, LLC (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004041189-A2 | A METHOD FOR INHIBITING CANCER DEVELOPMENT BY FATTY ACID SYNTHASE INHIBITORS | FASGEN LLC (US) | 2004-05-21 | — | — | WO | disclosed |
| EP-0651636-B1 | CHEMOTHERAPY FOR CANCER | UNIV JOHNS HOPKINS (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-0738107-B1 | INHIBITORS OF FATTY ACID SYNTHESIS AS ANTIMICROBIAL AGENTS | UNIV JOHNS HOPKINS (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-0738107-A4 | INHIBITORS OF FATTY ACID SYNTHESIS AS ANTIMICROBIAL AGENTS | UNIV JOHNS HOPKINS (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5710174-A | ANTICOAGULANTS FOR BLOOD DISORDERS | ZYMO GENETICS, INC. (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1997002340-A2 | METHODS FOR INHIBITING FACTOR XIII ACTIVITY | ZYMOGENETICS, INC. (US) | 1997-01-23 | — | — | WO | disclosed |
| WO-1996040671-A1 | CIS-RESORCYLIDE, PHARMACEUTICAL COMPOSITION CONTAINING IT, USE THEREOF IN THE TREATMENT OF THROMBOSIS AND RELATED DISORDERS | ZYMOGENETICS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0738107-A1 | INHIBITORS OF FATTY ACID SYNTHESIS AS ANTIMICROBIAL AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-10-23 | — | — | EP | disclosed |
| WO-1995019706-A1 | INHIBITORS OF FATTY ACID SYNTHESIS AS ANTIMICROBIAL AGENTS | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-07-27 | — | — | WO | disclosed |
| US-5188830-A | Intravenous administration of Factor XIIIa inhibitor | MERCK & CO., INC. (US) | 1993-02-23 | — | — | US | disclosed |
| US-5185149-A | Intravenously administering an acyloxiranecarboxylic acid compound factor XIII inhibitor to lyse clots | MERCK & CO., INC. (US) | 1993-02-09 | — | — | US | disclosed |
| US-4968494-A | FACTOR VIIIA INHIBITOR | MERCK & CO., INC. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0294016-A2 | Factor XIIIa inhibitor compounds useful for thrombolytic therapy | MERCK & CO. INC. (US) | 1988-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | ALDH1A1 942/4885F13A1 1952/4885MAPT 4597/4885 |
| US-20070142456-A1 | Method for inhibiting cancer development by fatty acid synthase inhibitors | FASN, SCD, FADS2 | ALDH1A1 549/4885F13A1 1162/4885MAPT 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.